PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Borbath, I.; Roychowdhury, S.; Goyal, L.; Lamarca, A.; Macarulla, T.; Shroff, R. T.; Oh, D. Y.; Javle, M. M.; Tamas, C.; Savastano, D. M.; Van Veenhuyzen, D. F.; Xu, C.; Solanas, J.; Freas, E. |
| Abstract Title: | PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500573 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.516 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 516 -- Source: Wos |
